OTC Markets OTCQB - Delayed Quote USD

(ONNVF)

1.5000

0.0000

(0.00%)

At close: March 26 at 4:00:00 PM EDT

Onco-Innovations' Inka Health Signs New Analytical Work with AstraZeneca Canada to Advance Real-World Evidence in Regulatory Science

VANCOUVER, BC / ACCESS Newswire / April 24, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), signed ...

ACCESS Newswire 8 days ago

ONNVF
0.00%
Dr. James Orbinski Joins Onco-Innovations' Scientific and Clinical Advisory Board to Bolster Company's Mission

VANCOUVER, BC / ACCESS Newswire / April 22, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointment of Dr. James Orbinski as a member of the Company's Scientific ...

ACCESS Newswire 10 days ago

ONNVF
0.00%
Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology

PNKP TechnologyShown in Past Study to Increase Survival Rate in Colorectal Cancer Bearing Mice VANCOUVER, BC / ACCESS Newswire / April 17, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company")is ...

ACCESS Newswire 15 days ago

ONNVF
0.00%
Onco-Innovations Announces Private Placement

Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / April 16, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") ...

ACCESS Newswire 16 days ago

ONNVF
0.00%
Onco-Innovations’ Inka Health Publishes Roche-Sponsored Study Advancing Real-World Oncology Research

VANCOUVER, BC / ACCESS Newswire / April 10, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its subsidiary, Inka Health Corp. ("Inka Health"), has published ...

ACCESS Newswire 22 days ago

ONNVF
0.00%
Onco-Innovations' Inka Health Completes Analytical Work for AstraZeneca Canada, Advancing Pharmaceutical Analytics and Leading to Key Studies at ISPOR 2025

VANCOUVER, BC / ACCESS Newswire / April 3, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), which ...

ACCESS Newswire 29 days ago

ONNVF
0.00%
Onco-Innovations' PKNP Technology Used with Radiation Therapy Shown in Study to Demonstrate Low Toxicity and High Safety Profile

VANCOUVER, BC / ACCESS Newswire / March 26, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding its second-generation nanoparticle formulation of ...

ACCESS Newswire last month

ONNVF
0.00%
Onco-Innovations Extends Marketing Program

VANCOUVER, BC / ACCESS Newswire / March 25, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that it has extended the term of its engagement with MCS Market Communication Service ...

ACCESS Newswire last month

ONNVF
0.00%
Onco-Innovations Provides Update on Use of Proceeds

VANCOUVER, BC / ACCESS Newswire / March 24, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H), (WKN: A3EKSZ ) (" Onco " or the " Company "), at the request of the Canadian Securities Exchange, provides, by way of the table below, ...

ACCESS Newswire last month

ONNVF
0.00%
Onco-Innovations' Licensed PNKP Inhibitor Technology Shown to Increase Sensitivity of Cancer Cells to Radiation in Animal Study

Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H ,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusive-licensed technology, a new class of Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors (the "Technology"), ...

ACCESS Newswire 2 months ago

ONNVF
0.00%
Onco-Innovations Completes Acquisition of Inka Health to Accelerate AI-Driven Cancer Research and Drug Development

Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news release dated January 22, 2025, that it has completed the acquisition (the "Acquisition") of all of the outstanding ...

ACCESS Newswire 2 months ago

ONNVF
0.00%
Onco-Innovations' Licensed Technology Shows Promise in Enhancing Chemotherapy Effectiveness by Overcoming Cancer Cell Resistance and Inhibiting Cancer Cell Repair

VANCOUVER, BC / ACCESS Newswire / January 30, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its licensed technology of a new class of PNKP (Polynucleotide Kinase ...

ACCESS Newswire 2 months ago

ONNVF
0.00%
Onco-Innovations' Private Placement Fully Subscribed

VANCOUVER, BC / ACCESS Newswire / January 29, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its non-brokered private placement (the "Private Placement") of up to 408,164 ...

ACCESS Newswire 3 months ago

ONNVF
0.00%
Onco-Innovations Unaware of Any Material Change

At the request of the Canadian Investment Regulatory Organization, Onco-Innovations Limited (the "Company") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent ...

ACCESS Newswire 3 months ago

ONNVF
0.00%

Performance Overview

Return	ONNVF	MSCI WORLD (^990100-USD-STRD)
YTD	+7.91%	+0.45%
1-Year	+7.91%	+10.81%
3-Year	+7.91%	+32.56%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

(ONNVF)

Onco-Innovations' Inka Health Signs New Analytical Work with AstraZeneca Canada to Advance Real-World Evidence in Regulatory Science

Dr. James Orbinski Joins Onco-Innovations' Scientific and Clinical Advisory Board to Bolster Company's Mission

Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology

Onco-Innovations Announces Private Placement

Onco-Innovations’ Inka Health Publishes Roche-Sponsored Study Advancing Real-World Oncology Research

Onco-Innovations' Inka Health Completes Analytical Work for AstraZeneca Canada, Advancing Pharmaceutical Analytics and Leading to Key Studies at ISPOR 2025

Onco-Innovations' PKNP Technology Used with Radiation Therapy Shown in Study to Demonstrate Low Toxicity and High Safety Profile

Onco-Innovations Extends Marketing Program

Onco-Innovations Provides Update on Use of Proceeds

Onco-Innovations' Licensed PNKP Inhibitor Technology Shown to Increase Sensitivity of Cancer Cells to Radiation in Animal Study

Onco-Innovations Completes Acquisition of Inka Health to Accelerate AI-Driven Cancer Research and Drug Development

Onco-Innovations' Licensed Technology Shows Promise in Enhancing Chemotherapy Effectiveness by Overcoming Cancer Cell Resistance and Inhibiting Cancer Cell Repair

Onco-Innovations' Private Placement Fully Subscribed

Onco-Innovations Unaware of Any Material Change

Performance Overview